glutathione persister cell Frontiers Low-GPX4 drives a sustained drug-tolerant
Description
Fernandes, L., Rodrigues-Pousada, C
First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, in patients with advanced solid tumors
They do not store personal data
The grid box site parameters was set up on xyz center coordinates at 73x68x73, and grid box size at (40x40x40)
